Editas Medicine, Inc. – NASDAQ:EDIT
Editas Medicine stock price today
$2.62
+1.41
+116.53%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Editas Medicine stock price monthly change
-78.16%
month
Editas Medicine stock price quarterly change
-78.16%
quarter
Editas Medicine stock price yearly change
-88.34%
year
Editas Medicine key metrics
Market Cap | 104.83M |
Enterprise value | 364.02M |
P/E | -2.14 |
EV/Sales | 18.46 |
EV/EBITDA | -1.73 |
Price/Sales | 23.41 |
Price/Book | 1.27 |
PEG ratio | 0.16 |
EPS | -2.1 |
Revenue | 69.40M |
EBITDA | -177.19M |
Income | -166.13M |
Revenue Q/Q | -88.47% |
Revenue Y/Y | 204.53% |
Profit margin | -1118.32% |
Oper. margin | -1146.31% |
Gross margin | 0% |
EBIT margin | -1146.31% |
EBITDA margin | -255.29% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEditas Medicine stock price history
Editas Medicine stock forecast
Editas Medicine financial statements
Average Price Target
$10.2
Potential upside: 289.31%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 2.88M | -40.29M | -1395.57% |
|---|---|---|---|
| Sep 2023 | 5.33M | -45.01M | -843.68% |
| Dec 2023 | 60.04M | -18.87M | -31.43% |
| Mar 2024 | 1.13M | -61.95M | -5458.15% |
| Jun 2023 | 541953000 | 142.03M | 26.21% |
|---|---|---|---|
| Sep 2023 | 504650000 | 144.18M | 28.57% |
| Dec 2023 | 499153000 | 150.05M | 30.06% |
| Mar 2024 | 440347000 | 145.94M | 33.14% |
| Jun 2023 | -38.71M | 12.98M | 117.52M |
|---|---|---|---|
| Sep 2023 | -35.45M | -102.82M | 0 |
| Dec 2023 | -22.24M | 62.84M | 514K |
| Mar 2024 | -49.87M | -4.74M | 192K |
Editas Medicine alternative data
Company's Focus On
| 19 Feb 2023 | 1 | 2 | 2 | 15 | 1 |
|---|---|---|---|---|---|
| 26 Feb 2023 | 0 | 1 | 2 | 16 | 0 |
| 5 Mar 2023 | 0 | 1 | 1 | 17 | 0 |
| 12 Mar 2023 | 0 | 1 | 3 | 15 | 0 |
| 19 Mar 2023 | 0 | 2 | 3 | 18 | 0 |
| 26 Mar 2023 | 0 | 1 | 3 | 18 | 0 |
| 2 Apr 2023 | 0 | 1 | 2 | 21 | 0 |
| 9 Apr 2023 | 0 | 1 | 3 | 20 | 0 |
| 16 Apr 2023 | 0 | 1 | 3 | 18 | 0 |
| 23 Apr 2023 | 0 | 1 | 2 | 18 | 1 |
| 30 Apr 2023 | 0 | 1 | 3 | 19 | 0 |
| 7 May 2023 | 0 | 1 | 3 | 19 | 0 |
| 14 May 2023 | 0 | 1 | 3 | 17 | 0 |
| 21 May 2023 | 0 | 1 | 2 | 17 | 0 |
| 28 May 2023 | 0 | 1 | 3 | 19 | 0 |
| 4 Jun 2023 | 1 | 2 | 3 | 16 | 0 |
| 11 Jun 2023 | 0 | 1 | 3 | 15 | 0 |
| 18 Jun 2023 | 0 | 1 | 3 | 18 | 0 |
| 25 Jun 2023 | 0 | 1 | 2 | 19 | 0 |
| 2 Jul 2023 | 0 | 1 | 3 | 18 | 0 |
Gene Editing
| 9 Jul 2023 | 19 |
|---|---|
| 16 Jul 2023 | 20 |
| 23 Jul 2023 | 19 |
| 30 Jul 2023 | 19 |
| 6 Aug 2023 | 24 |
| 13 Aug 2023 | 27 |
| 20 Aug 2023 | 29 |
| 27 Aug 2023 | 28 |
| 3 Sep 2023 | 28 |
| 10 Sep 2023 | 46 |
| 17 Sep 2023 | 37 |
| 24 Sep 2023 | 27 |
| 1 Oct 2023 | 33 |
| 8 Oct 2023 | 26 |
| 15 Oct 2023 | 30 |
| 22 Oct 2023 | 34 |
| 29 Oct 2023 | 33 |
| 5 Nov 2023 | 38 |
| 12 Nov 2023 | 42 |
| 19 Nov 2023 | 31 |
Gene Editing Companies
| 19 Feb 2023 | 0 | 5 | 0 | 7 | 15 |
|---|---|---|---|---|---|
| 26 Feb 2023 | 0 | 5 | 0 | 3 | 12 |
| 5 Mar 2023 | 1 | 5 | 0 | 3 | 5 |
| 12 Mar 2023 | 0 | 3 | 0 | 2 | 7 |
| 19 Mar 2023 | 0 | 1 | 0 | 6 | 7 |
| 26 Mar 2023 | 0 | 4 | 0 | 5 | 9 |
| 2 Apr 2023 | 0 | 5 | 0 | 7 | 5 |
| 9 Apr 2023 | 0 | 3 | 1 | 2 | 3 |
| 16 Apr 2023 | 0 | 0 | 0 | 5 | 12 |
| 23 Apr 2023 | 0 | 5 | 0 | 8 | 11 |
| 30 Apr 2023 | 0 | 2 | 1 | 5 | 10 |
| 7 May 2023 | 0 | 3 | 0 | 6 | 6 |
| 14 May 2023 | 7 | 2 | 1 | 3 | 5 |
| 21 May 2023 | 0 | 5 | 2 | 5 | 9 |
| 28 May 2023 | 2 | 2 | 0 | 9 | 10 |
| 4 Jun 2023 | 0 | 3 | 0 | 7 | 3 |
| 11 Jun 2023 | 0 | 2 | 0 | 7 | 4 |
| 18 Jun 2023 | 2 | 4 | 0 | 10 | 10 |
| 25 Jun 2023 | 0 | 15 | 1 | 11 | 31 |
| 2 Jul 2023 | 0 | 7 | 0 | 11 | 22 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 14 |
|---|---|
| Sep 2023 | 22 |
| Oct 2023 | 24 |
| Nov 2023 | 18 |
| Dec 2023 | 15 |
| Jan 2024 | 15 |
| Feb 2024 | 20 |
| Apr 2024 | 22 |
| May 2024 | 11 |
| Jun 2024 | 11 |
| Jul 2024 | 12 |
| Dec 2024 | 3 |
| Jan 2025 | 0 |
| Feb 2025 | 1 |
| May 2025 | 0 |
| Jul 2025 | 1 |
| Aug 2025 | 0 |
| Aug 2023 | 226 |
|---|---|
| Sep 2023 | 226 |
| Oct 2023 | 226 |
| Nov 2023 | 226 |
| Dec 2023 | 226 |
| Jan 2024 | 226 |
| Feb 2024 | 226 |
| Mar 2024 | 265 |
| Apr 2024 | 265 |
| May 2024 | 265 |
| Jun 2024 | 265 |
| Jul 2024 | 265 |
Editas Medicine other data
68.79%
+2.50%
of EDIT is owned by hedge funds
237
-2
47.11M
+2.28M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 0 | 98151 |
| May 2024 | 45000 | 22337 |
| Jun 2024 | 0 | 12702 |
| Jul 2024 | 0 | 18505 |
| Sep 2024 | 0 | 2073 |
| Dec 2024 | 0 | 2159 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | O'NEILL GILMORE NEIL director, officer.. | Common Stock | 1,618 | $2.08 | $3,361 | ||
Sale | O'NEILL GILMORE NEIL director, officer.. | Common Stock | 1,618 | $2.08 | $3,361 | ||
Sale | MEI BAISONG officer: EVP, CHIEF MEDICAL OFF.. | Common Stock | 541 | $2.08 | $1,124 | ||
Sale | MEI BAISONG officer: EVP, CHIEF MEDICAL OFF.. | Common Stock | 518 | $3.43 | $1,774 | ||
Sale | O'NEILL GILMORE NEIL director, officer.. | Common Stock | 1,555 | $3.43 | $5,326 | ||
Sale | O'NEILL GILMORE NEIL director, officer.. | Common Stock | 1,555 | $3.43 | $5,326 | ||
Sale | BURKLY LINDA officer: EVP, CHIEF SCIENTIFIC .. | Common Stock | 11,886 | $5.42 | $64,375 | ||
Sale | MEI BAISONG officer: EVP, CHIEF MEDICAL OFF.. | Common Stock | 6,619 | $5.21 | $34,459 | ||
Sale | O'NEILL GILMORE NEIL director, officer.. | Common Stock | 12,191 | $5.5 | $67,002 | ||
Sale | O'NEILL GILMORE NEIL director, officer.. | Common Stock | 12,191 | $5.5 | $67,002 |
| Patent |
|---|
Application Filling date: 11 Oct 2021 Issue date: 1 Sep 2022 |
Grant Filling date: 31 Mar 2020 Issue date: 19 Jul 2022 |
Grant Filling date: 26 Apr 2019 Issue date: 19 Jul 2022 |
Grant Filling date: 6 May 2016 Issue date: 19 Jul 2022 |
Application Filling date: 20 Dec 2021 Issue date: 16 Jun 2022 |
Application CELLS EXPRESSING A RECOMBINANT RECEPTOR FROM A MODIFIED TGFBR2 LOCUS, RELATED POLYNUCLEOTIDES AND METHODS Filling date: 30 Apr 2020 Issue date: 16 Jun 2022 |
Application Filling date: 14 Jul 2021 Issue date: 9 Jun 2022 |
Grant Filling date: 2 Aug 2017 Issue date: 24 May 2022 |
Application Filling date: 14 Feb 2020 Issue date: 12 May 2022 |
Application Filling date: 7 Jun 2021 Issue date: 5 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 3 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
Undercovered Dozen: Virgin Galactic, Gold Fields, Matador Resources, EHang +
Editas And Intellia: Strategic Shifts And Long-Term Investment Potential
CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers
CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big
Editas Medicine: A Mispriced Contender In The Gene Editing Arena
Editas Medicine: RUBY Gems, Sparkling Catalysts In Sickle Cell Arena
Editas Medicine Bolsters Cash Position Amidst Slow And Steady Progress
bluebird bio: A Risk Worth Taking
-
What's the price of Editas Medicine stock today?
One share of Editas Medicine stock can currently be purchased for approximately $2.62.
-
When is Editas Medicine's next earnings date?
Unfortunately, Editas Medicine's (EDIT) next earnings date is currently unknown.
-
Does Editas Medicine pay dividends?
No, Editas Medicine does not pay dividends.
-
How much money does Editas Medicine make?
Editas Medicine has a market capitalization of 104.83M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 296.32% to 78.12M US dollars.
-
What is Editas Medicine's stock symbol?
Editas Medicine, Inc. is traded on the NASDAQ under the ticker symbol "EDIT".
-
What is Editas Medicine's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Editas Medicine?
Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Editas Medicine's key executives?
Editas Medicine's management team includes the following people:
- Ms. Michelle Robertson Chief Financial Officer, Principal Accounting Officer, Treasurer & Assistant Sec.(age: 58, pay: $647,260)
- Dr. Lisa A. Michaels M.D. Executive Vice President & Chief Medical Officer(age: 60, pay: $213,470)
- Mr. James C. Mullen Chairman, Pres & Chief Executive Officer(age: 66, pay: $100,500)
-
How many employees does Editas Medicine have?
As Jul 2024, Editas Medicine employs 265 workers.
-
When Editas Medicine went public?
Editas Medicine, Inc. is publicly traded company for more then 9 years since IPO on 3 Feb 2016.
-
What is Editas Medicine's official website?
The official website for Editas Medicine is editasmedicine.com.
-
Where are Editas Medicine's headquarters?
Editas Medicine is headquartered at 11 Hurley Street, Cambridge, MA.
-
How can i contact Editas Medicine?
Editas Medicine's mailing address is 11 Hurley Street, Cambridge, MA and company can be reached via phone at +61 74019000.
-
What is Editas Medicine stock forecast & price target?
Based on 5 Wall Street analysts` predicted price targets for Editas Medicine in the last 12 months, the avarage price target is $10.2. The average price target represents a 289.31% change from the last price of $2.62.
Editas Medicine company profile:
Editas Medicine, Inc.
editasmedicine.comExchange:
NASDAQ
Full time employees:
265
Industry:
Biotechnology
Sector:
Healthcare
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
11 Hurley Street
Cambridge, MA 02141
Cambridge, MA 02141
CIK: 0001650664
ISIN: US28106W1036
CUSIP: 28106W103
